Risk Factors for Frontal Fibrosing Alopecia
The association of frontal fibrosing alopecia with demographic and exposition factors in a multiracial population was evaluated.
The association of frontal fibrosing alopecia with demographic and exposition factors in a multiracial population was evaluated.
The racial and ethnic distribution of common dermatologic disorders seen at a US tertiary care center are characterized.
Men with severe hair loss were significantly more likely to test positive for COVID-19, finds study data.
For patients with chronic alopecia areata, fractional laser treatment may present a therapeutic alternative.
Women with frontal fibrosing alopecia were found to have a higher prevalence of autoimmune disease, thyroid hormone abnormalities, and estrogen deficiency compared with the general population.
High prevalence and ethnic variation of scalp pruritus and hair loss were noted in a general dermatology population.
The use of spironolactone for alopecia was not associated with estrogen-dependent cancer recurrence.
The FDA has granted Breakthrough Therapy designation to baricitinib (LY3009104; Lilly), an oral Janus Kinase (JAK) inhibitor, for the treatment of alopecia areata.
A survey found that dermatologists have more confidence in diagnosing, managing, and their personal knowledge of permanent chemotherapy-induced alopecia compared with clinicians who practice in oncology or primary care/internal medicine.
A review of the unique transition-related medical and aesthetic dermatologic needs of patients undergoing transition.